Compare DRVN & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRVN | NNNN |
|---|---|---|
| Founded | 1972 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Automotive Aftermarket | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 2020 | N/A |
| Metric | DRVN | NNNN |
|---|---|---|
| Price | $12.54 | $27.96 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $19.57 | N/A |
| AVG Volume (30 Days) | ★ 2.0M | 17.9K |
| Earning Date | 05-05-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 59.82 | N/A |
| EPS | ★ 0.69 | N/A |
| Revenue | ★ $2,339,588,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.53 | N/A |
| P/E Ratio | ★ $18.15 | $446.57 |
| Revenue Growth | ★ 1.54 | N/A |
| 52 Week Low | $9.80 | $5.99 |
| 52 Week High | $19.74 | $55.65 |
| Indicator | DRVN | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 53.00 | 61.11 |
| Support Level | $9.92 | $26.48 |
| Resistance Level | $15.91 | $30.70 |
| Average True Range (ATR) | 0.62 | 2.12 |
| MACD | 0.22 | 0.59 |
| Stochastic Oscillator | 69.57 | 87.64 |
Driven Brands Holdings Inc is an automotive services company in North America. Its platform provides high-quality services to an extensive range of retail and commercial customers. The company provides an extensive range of core consumer and commercial automotive needs, including paint, collision, glass, and repair services, as well as a variety of high-frequency services, such as oil changes and car washes. The company segments include: Maintenance, Car Wash, Paint, Collision & Glass, and Platform Services. It derives maximum revenue from Maintenance Segment. Geographically, the company operates into United States, Canada and Rest of the World.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.